Abstract: Described herein are coating compositions for consumer and/or medical products. The coating compositions can be used to confer desirable properties to the consumer and/or medical products.

Abstract: Described herein are coating compositions for consumer and/or medical products. The coating compositions can be used to confer desirable properties to the consumer and/or medical products.

Abstract: Described herein are coating compositions for consumer and/or medical products. The coating compositions can be used to confer desirable properties to the consumer and/or medical products.

Abstract: Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site. Methods of forming the adhesive and making the coated vascular grafts are also disclosed.

Abstract: Described herein are coating compositions for consumer and/or medical products. The coating compositions can be used to confer desirable properties to the consumer and/or medical products.

Abstract: Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site. Methods of forming the adhesive and making the coated vascular grafts are also disclosed.

Abstract: Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site. Methods of forming the adhesive and making the coated vascular grafts are also disclosed.

Abstract: Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site. Methods of forming the adhesive and making the coated vascular grafts are also disclosed.

Abstract: The present invention relates to a vascular stent that includes an expandable stent defining an interior compartment, a first polymeric layer exposed to the interior compartment defined by the stent, the first layer comprising an agent that promotes re-endothelialization, an agent that inhibits thrombosis, or a combination thereof, and a second polymeric layer at least partially external of the stent, the second layer being adapted for contacting a vascular surface and being characterized by pores that are substantially impermeable to vascular smooth muscle cell migration. Method of making and using the vascular stent are also disclosed.

Abstract: Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site. Methods of forming the adhesive and making the coated vascular grafts are also disclosed.

Abstract: Methods for measuring platelet aggregation in a blood sample, for measuring the efficacy of anti-platelet therapies at the point of care, and for detecting the presence of platelet micro-aggregates in a blood sample. Several differences between the methods of the present invention and previously disclosed procedures for practicing such methods while using a hematology analyzer will allow for achieving about 0.98 correlation relative to light transmission aggregometry. These differences allow the methods of the present invention to be used at the point of care for assessing, e.g., the efficacy of anti-platelet therapy, particularly GPIIb-IIIa antagonists.